Adagene Inc
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 anti… Read more
Adagene Inc (ADAG) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.294x
Based on the latest financial reports, Adagene Inc (ADAG) has a cash flow conversion efficiency ratio of -0.294x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.16 Million) by net assets ($37.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Adagene Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Adagene Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Adagene Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adagene Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sun Max Tech Ltd
TW:6591
|
0.040x |
|
Jayamas Medica Industri
JK:OMED
|
0.028x |
|
Alembic Limited
NSE:ALEMBICLTD
|
0.020x |
|
Indústrias Romi S.A
SA:ROMI3
|
-0.005x |
|
THN Corporation
KO:019180
|
0.100x |
|
ARTHA RESOURCES
F:16T
|
0.516x |
|
NewFlex Technology Co. Ltd
KQ:085670
|
0.030x |
|
Kellton Tech Solutions Limited
NSE:KELLTONTEC
|
0.001x |
Annual Cash Flow Conversion Efficiency for Adagene Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Adagene Inc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $50.52 Million | $-29.70 Million | -0.588x | -45.77% |
| 2023-12-31 | $70.56 Million | $-28.45 Million | -0.403x | +31.07% |
| 2022-12-31 | $83.09 Million | $-48.61 Million | -0.585x | -110.98% |
| 2021-12-31 | $156.56 Million | $-43.41 Million | -0.277x | -186.89% |
| 2020-12-31 | $-89.39 Million | $-28.53 Million | 0.319x | +0.23% |
| 2019-12-31 | $-57.01 Million | $-18.15 Million | 0.318x | -8.42% |
| 2018-12-31 | $-41.03 Million | $-14.26 Million | 0.348x | -- |